Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 7/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993594 | 0.91 | NAMPT (0.44) | NAMPTACKR3KMT2ASMN1; SMN2 | |
| SCHEMBL1989364 | 0.90 | KMT2A (0.42) | CYP3A4NAMPTMEN1RAB9AKMT2A | |
| SCHEMBL1990367 | 0.89 | TP53 (0.36) | KMT2ASMN1; SMN2 | |
| SCHEMBL1993928 | 0.87 | ALDH1A1 (0.44) | CYP3A4NAMPTL3MBTL1ACKR3MEN1 | |
| SCHEMBL1990478 | 0.87 | MEN1 (0.36) | L3MBTL1MEN1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL1989763 | 0.86 | CYP3A4 (0.38) | CYP3A4MEN1KMT2A | |
| SCHEMBL976720 | 0.85 | TP53 (0.35) | — | |
| SCHEMBL1990735 | 0.85 | NAMPT (0.36) | NAMPTMEN1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL1992284 | 0.84 | CYP11B2 (0.45) | NAMPTMEN1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL1989941 | 0.84 | MAPK14 (0.39) | MAPK14NAMPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | claimed |
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | C1R, TACR1, C1S | CYP3A4 846/4885MAPK14 4644/4885NAMPT 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.